Evolus’ (EOLS) Buy Rating Reaffirmed at HC Wainwright

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $27.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 65.44% from the company’s previous close.

EOLS has been the subject of a number of other reports. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Friday, September 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research note on Monday, September 16th. Finally, Barclays upped their target price on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th.

Evolus Stock Performance

NASDAQ EOLS opened at $16.32 on Friday. The firm has a market cap of $1.03 billion, a P/E ratio of -17.93 and a beta of 1.31. The company’s 50 day moving average is $16.21 and its 200-day moving average is $13.66. Evolus has a 12-month low of $7.44 and a 12-month high of $17.82. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 6.26.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $66.91 million for the quarter, compared to the consensus estimate of $65.06 million. Sell-side analysts predict that Evolus will post -0.64 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Sandra Beaver sold 3,276 shares of the firm’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the sale, the chief financial officer now owns 148,502 shares in the company, valued at approximately $2,224,559.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now directly owns 148,502 shares in the company, valued at approximately $2,224,559.96. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the transaction, the chief marketing officer now owns 82,375 shares in the company, valued at $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Evolus

A number of hedge funds have recently made changes to their positions in the business. Quest Partners LLC bought a new position in shares of Evolus during the 2nd quarter valued at $43,000. Quarry LP purchased a new stake in shares of Evolus during the second quarter valued at approximately $54,000. Profund Advisors LLC purchased a new stake in shares of Evolus during the second quarter valued at approximately $130,000. Arizona State Retirement System increased its stake in shares of Evolus by 9.4% in the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock worth $158,000 after buying an additional 1,253 shares during the period. Finally, ProShare Advisors LLC increased its stake in shares of Evolus by 9.9% in the first quarter. ProShare Advisors LLC now owns 11,542 shares of the company’s stock worth $162,000 after buying an additional 1,035 shares during the period. 90.69% of the stock is currently owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.